In the present study, we show that the benefits of treatment with full-spectrum CBD oil for non-syndromic individuals with ASD are not only noticeable to the clinical eye but are also perceived and experienced by the families and caregivers. In short, the findings corroborate that this treatment, combined with a gradual and individualized dosage regimen, is safe and efficient for broader treatment of central and comorbid symptoms associated with ASD, being able to improve aspects such as social interaction, communication and quality of life.
World First Australian & New Zealand Trial of Cannabidiol Transdermal Gel For Hard-to-Treat Epilepsy
January 21, 2025
Professor Terry O’Brien and his team have taken a slick approach to battling hard-to-treat epilepsy with a groundbreaking transdermal cannabidiol (CBD) gel. Here’s the scoop: After 6 months
